Sep
25
2023
Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia
Topline data for RECOVER trial on track for October 2023CUPERTINO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) — Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical …